Streck, a member of Bio Nebraska, announced the commercialization of the Streck® Viral Extraction Kit with partner Ceres Nanosciences.
Announcement from Streck
Streck is pleased to announce the commercialization of Streck® Viral Extraction Kit with partner Ceres Nanosciences. Streck has developed a viral extraction kit utilizing Nanotrap® technology to shorten hands-on time and simplify the workflow of the isolation of SARS-CoV-2 and Influenza A from clinical samples.
Labs across the world have been testing clinical samples for SARS-CoV-2 over the past three years. These labs have developed, maintained, and tirelessly performed testing methods under the demand of the pandemic, producing clinically relevant results for their communities. This inspired Streck to develop a kit to reduce time spent on RNA extraction to enable labs to reach a higher throughput and ultimately free up time for lab professionals.
The eluted samples are ready for downstream analysis using a variety of techniques such as qPCR, ddPCR, or sequencing. The pre-mixed buffers eliminate the need for additional chemicals or reconstitution so laboratory professionals can hit the bench running and have eluted samples ready for downstream analysis in less than 30 minutes.
Streck, in partnership with Ceres Nanosciences, distributes Nanotrap Magnetic Virus Particles and the Nanotrap Enhancement Reagents for wastewater testing. The new extraction kit offers a solution for clinical samples containing SARS-CoV-2 and Influenza A. “Expanding our partnership with Ceres Nanosciences to commercialize a kit for clinical respiratory samples bolsters Streck’s reach in a new and exciting way,” said Matt Kreifels, Vice President of Sales and Business Development. “We are thrilled to offer a product that both simplifies and accelerates the workflow for RNA extraction.”